Stocks paused to catch their breath today, if you can call it that, while they sit only slightly in red, after the blue chips set several marginal new records in recent sessions. Much as we’d like to cheer on stocks, we can’t make a compelling case for a big advance… Read More
Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.
Analyst Articles
We’ll continue to take our trading cues from our market indicators, however, which at the moment are all essentially neutral. We did get one opportunity last week to place a trade based on the projection of our oil indicator. Rather than playing oil directly, however, we chose to speculate on… Read More
Sell Idenix Pharmaceuticals (IDIX). The week begins with great news for Idenix Pharmaceuticals (IDIX)! Merck has reached agreement to buy out Idenix for $3.85 billion in cash, or $24.50 per share, more than triple Idenix’s Friday closing price. We recommend selling and taking the huge profit. We are selling… Read More
As it does the first Friday of every month, the Bureau of Labor Statistics released its assessment of the job market today. In May, the U.S. added 217,000 jobs (slightly better than the consensus expectation). The U.S. has now officially recovered the 8.7 million jobs lost during the recession, which… Read More
Sell to close the Market Vectors Oil Services ETF (OIH) October 54 call option, at the market. We’ve enjoyed a nice rise in our call option in the past two days; now it’s time to lock in our gain. While our oil indicator is still positive, our stock indicator… Read More
Buy to open the Market Vectors Oil Services ETF (OIH) October 54 call option. Use a limit order to pay no more than $2.15 per contract. This is proving to be a highly unusual time in which the vast majority of our indicators are essentially dead neutral. The lone… Read More
Theravance (THRX) has completed the spinoff of the developmental assets in its pipeline. The new company is called Theravance Biopharma and trades under the ticker symbol TBPH. As a result of the split, THRX shareholders received two shares of TBPH for every seven shares of THRX owned. Any fractional shares… Read More
In spite of the encouraging economic data from around the globe, we remain lukewarm on the prospect for a further short-term advance in stocks beyond current levels. But our neutral market indicators also don’t foresee any sort of correction either, much as we’d like to take a position on one… Read More
Earlier this week, following the lead of another top hedge fund, we bought shares in a Chinese online retailer specializing in flash sales of discounted merchandise. Founded in 2008, the company has achieved tremendous growth through leveraging China’s expanding middle class and its appetite for brand-name apparel and low prices. Annual revenue has exploded from just $2.8 million in 2009, the first full year of operations, to $1.7 billion in 2013. The company also passed an important milestone: it reached profitability for the first time last year, with net income of $52.3 million, compared to a $9.5 million loss for 2012. If early 2014 results provide any indication, the momentum is still very strong. Read More
We are buying an approximate 4.5 percent position in Vipshop Holdings Limited (VIPS). As we are already fully invested, to raise cash for the purchase, we are reducing our positions in ViaSat (VSAT) and Sirius XM Holdings (SIRI) to roughly 6 percent each. Chase Coleman III’s Tiger Global Management… Read More